Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. Co. is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. Co.'s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. We show 45 historical shares outstanding datapoints in our ATRA shares outstanding history coverage, used to compute ATRA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATRA market cap history over the course of time is important for investors
interested in comparing ATRA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATRA versus a peer is one thing; comparing
ATRA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATRA can fluctuate over the course of history.
With this page we aim to empower investors researching ATRA by allowing them to research the ATRA market cap history. |
Free ATRA Email Alerts:
Video: The Importance of Market Cap
